玻璃体腔抗VEGF药物对糖尿病患者肾功能的影响
单中心回顾性观察研究纳入45例接受玻璃体腔抗VEGF治疗的2型糖尿病患者并与45例特征相近对照比较。12个月时76.3%患者存在慢性肾脏病(CKD),估算肾小球滤过率(eGFR)平均下降19.4%;24个月时80%存在CKD,eGFR平均下降28%。抗VEGF组eGFR斜率为10 ml/min/年,对照组为1.5 ml/min/年(P < 0.05)。
要点
- 玻璃体腔抗VEGF治疗后eGFR下降明显快于对照(10 vs 1.5 ml/min/年,P < 0.05)
- 既往CKD者随访中需肾替代治疗比例较高,风险因素包括年龄、既往CKD与基线蛋白尿
- 用药前应评估肾功能与蛋白尿,对高危患者权衡抗VEGF使用
核心结论
- 玻璃体腔抗VEGF治疗是2型糖尿病患者发生CKD及既往CKD患者快速进展至终末期肾病的危险因素。
研究设计与样本
- 单中心、回顾性、观察性研究,纳入45例接受抗VEGF治疗的2型糖尿病患者(55.6%男性,平均年龄74.4±11.5岁,范围50-91岁),与45例特征相近患者对照。
主要发现
- 12个月时76.3%患者存在CKD,eGFR平均下降19.4%。
- 12个月时9例(20%)eGFR下降>25%,3例(6.7%)肾小球滤过率下降>50%。
- 24个月时80%患者存在CKD,eGFR平均下降28%。
- 抗VEGF组eGFR斜率10 ml/min/年,对照组1.5 ml/min/年(P < 0.05)。
- CKD组首次给药后5例(17.2%)随访中需肾替代治疗,平均时间22±12个月。
关键数值与推荐
- 需透析的主要危险因素为年龄、既往CKD和基线蛋白尿。
临床怎么用
- 对糖尿病患者启动玻璃体腔抗VEGF前应评估肾功能与蛋白尿,并在治疗中监测eGFR变化。
- 对既往CKD或基线蛋白尿患者应谨慎权衡抗VEGF使用,避免CKD进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Intravitreal administration of vascular endothelial growth factor inhibitors (anti-VEGF) is the treatment of choice in retinal pathology associated with type 2 diabetes mellitus (DM2). We aimed to analyze the effect of intravitreal anti-VEGF administration on renal function in patients with DM2. METHODS: This is a single-center retrospective and observational study of patients with DM2 with and without chronic kidney disease (CKD). We analyzed the evolution of renal function after anti-VEGF onset, compared with a control group. RESULTS: We included 45 patients (55.6% male) who received anti-VEGF therapy. Mean age was 74.4±11.5 (50-91) years. These were compared with 45 patients with similar characteristics. After 12 months, 76.3% had CKD with a mean reduction in estimated glomerular filtration rate (eGFR) of 19.4%. Nine patients (20%) had a >25% reduction in eGFR, and 3 patients (6.7%) had a >50% reduction in GFR. At 24 months, 80% of patients had CKD with a mean eGFR decrease of 28%. The mean eGFR slope of patients who had received anti-VEGF treatment was 10 ml/min/year compared to 1.5 ml/min/year in the control group (P < 0.05). After the first administration, 5 patients (17.2%) in the CKD group required renal replacement therapy during follow-up (mean time 22±12 months). Main risk factors for need of dialysis were age, presence of previous CKD, and baseline proteinuria. CONCLUSION: Intravitreal anti-VEGF administration is a risk factor for CKD and rapid progression to end-stage kidney disease in patients with previous CKD. Knowing these drugs' implications is crucial to avoid CKD progression and opportunely limit their use in certain patients.
引用
- Rivero M, Fernández-Vidal M, Sandino J, et al. Effect of Intravitreal Anti-Endothelial Growth Factor Agents on Renal Function in Patients With Diabetes Mellitus. Kidney Int Rep. 2024. PMID: 38707827. doi:10.1016/j.ekir.2024.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。